针对CD33分子的抗体偶联药物的研究进展.pdfVIP

网络出版时间：2013-12-17 09:35 网络出版地址：/kcms/doi/10.11844/cjcb.2014.01.0236.html 中国细胞生物学学报 Chinese Journal of Cell Biology 2014, 36(1): DOI: 10.11844/cj cb.2014.01.0236 针对CD33分子的抗体偶联药物的研究进展 张珍珍 丁 倩 汤 沁 李红蕊 詹金彪* (浙江大学医学院生物化学系, 杭州310058) 摘要 近年来随着抗体人源化技术的进步, 抗体药物在肿瘤临床治疗领域取得了突破性进 展, 逐渐成为全球生物制药领域的热点。CD33分子是免疫球蛋白超家族成员, 同时也是唾液酸依 赖的免疫球蛋白样凝集素家族的成员, 在免疫调节过程中具有重要作用。CD33分子特异表达于白 血病细胞表面而在造血干细胞中不表达, 因而成为白血病免疫治疗的理想靶点。以CD33为靶点的 抗体药物主要有CMA676、HUM 195、AVE9633、WM53及HIM3-4等, 目前大多处于临床试验阶段。 该实验室也在进行抗CD33全人源抗体的研究, 利用噬菌体展示技术筛选与CD33胞外区特异性结 合的单链抗体, 并构建免疫毒素和抗体偶联药物以研究其体内外抗肿瘤作用。该文针对CD33分子 及其抗体偶联药物的现状及趋势作一综述。 关键词 CD33分子; 抗体偶联药物; 免疫毒素; 白血病; 靶向治疗 Progress in Antibody-Drug Conjugates Directed against CD33 Zhang Zhenzhen, Ding Qian, Tang Qin, Li Hongrui, Zhan Jinbiao* (Department of Biochemistry, Zhejiang University School of Medicine, Hangzhou 310058, China) Abstract Monoclonal antibody has become an important drug modality for the treatment of cancer, with the advantages of low molecular weight, low toxic effect and precise targeting. CD33 belongs to the immunoglobulin superfamily and is one of the sialic acid dependent IG-like lectin family, which plays an important role in the immune system. Most acute myelocytic leukemia (AML) cells, but not the surface of stem cells, have CD33 overexpression which makes the molecule an ideal target for AML therapy. Several antibody drugs directed against CD33 including HUM195, CMA676, AVE9633, WM53 and HIM3-4 have been reported. In our lab, a phage-displayed human antibody library has been constru